US Patent

US9517220 — Bromfenac bioavailability

Method of Use · Assigned to Bausch and Lomb Pharma Holdings Corp · Expires 2033-11-11 · 7y remaining

Vulnerability score 45/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects formulations and methods that enhance bromfenac penetration into ocular tissue when topically administered.

USPTO Abstract

Formulations and methods that provided enhanced bromfenac penetration into ocular tissue when topically administered, compared to the currently available BROMDAYâ¢ formulation and method when topically administered. The formulations and methods did so while retaining the patient convenience of a once-daily administration and advantageously lowered the bromfenac concentration dosed to the patient.

Drugs covered by this patent

bromfenac-sodium (BROMFENAC SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1933`	—	bromfenac-sodium

Patent Metadata

Patent number: US9517220
Jurisdiction: US
Classification: Method of Use
Expires: 2033-11-11
Drug substance claim: No
Drug product claim: No
Assignee: Bausch and Lomb Pharma Holdings Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.